ADORA3 and psoriasis: Piclidenoson (CF-101; Can-Fite BioPharma) is an A3AR agonist which recently gained approval by the European Medicines Agency and the U.S. Food and Drug Administration (April 2023 and June 2023, respectively) to initiate phase III registration trials for psoriasis [90,91].